These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 11216334)

  • 21. Paroxetine. A pharmacoeconomic evaluation of its use in depression.
    Wilde MI; Whittington R
    Pharmacoeconomics; 1995 Jul; 8(1):62-81. PubMed ID: 10155603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy--results from a managed care administrative claims database.
    Eaddy MT; Druss BG; Sarnes MW; Regan TS; Frankum LE
    J Manag Care Pharm; 2005 Mar; 11(2):145-50. PubMed ID: 15766321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database.
    Coupland CA; Dhiman P; Barton G; Morriss R; Arthur A; Sach T; Hippisley-Cox J
    Health Technol Assess; 2011 Aug; 15(28):1-202, iii-iv. PubMed ID: 21810375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The management of depression: the implications for managed care--roundtable discussion: Part 2.
    Arikian S; Casciano J; Kang-Cipolla L; Vodoor M; Grubin M; Clark D; Waugh W; Kelsey J; Osborn LW
    Manag Care Interface; 2000; Suppl B():19-25, 32. PubMed ID: 11183021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program.
    Hamer AM; Hartung DM; Haxby DG; Ketchum KL; Pollack DA
    J Manag Care Pharm; 2006; 12(6):449-56. PubMed ID: 16925452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.
    Armstrong EP; Skrepnek GH; Haim Erder M
    Curr Med Res Opin; 2007 Feb; 23(2):251-8. PubMed ID: 17288678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
    Shih YC; Bekele NB; Xu Y
    Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pharmacoeconomic study of the management of major depression: patients in a TennCare HMO.
    Smith W; Sherrill A
    Med Interface; 1996 Jul; 9(7):88-92. PubMed ID: 10159282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder.
    Endicott J; McLaughlin TP; Grudzinski AN
    J Clin Psychiatry; 2003 Dec; 64(12):1511-6. PubMed ID: 14728114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluoxetine. A pharmacoeconomic review of its use in depression.
    Wilde MI; Benfield P
    Pharmacoeconomics; 1998 May; 13(5 Pt 1):543-61. PubMed ID: 10180753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial.
    Kendrick T; Peveler R; Longworth L; Baldwin D; Moore M; Chatwin J; Thornett A; Goddard J; Campbell M; Smith H; Buxton M; Thompson C
    Br J Psychiatry; 2006 Apr; 188():337-45. PubMed ID: 16582060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using forecasting models to estimate the effects of changes in the composition of claims for selective serotonin reuptake inhibitors on expenditures.
    Dewa CS; Hoch JS; Goering P
    Clin Ther; 2001 Feb; 23(2):292-306. PubMed ID: 11293562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the comparative-effectiveness of antidepressants commonly prescribed for depression in the US Medicare population.
    Kaplan C; Zhang Y
    J Ment Health Policy Econ; 2012 Dec; 15(4):171-8. PubMed ID: 23525835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depression and pain: an appraisal of cost effectiveness and cost utility of antidepressants.
    Pan YJ; Pan CH; Chan HY; Kuo KH
    J Psychiatr Res; 2015 Apr; 63():123-31. PubMed ID: 25727051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.
    Polsky D; Onesirosan P; Bauer MS; Glick HA
    J Clin Psychiatry; 2002 Feb; 63(2):156-64. PubMed ID: 11874218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A critical review of selected pharmacoeconomic analyses of antidepressant therapy.
    Conner TM; Crismon ML; Still DJ
    Ann Pharmacother; 1999 Mar; 33(3):364-72. PubMed ID: 10200863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of antidepressant treatments on health service utilization and medical costs among patients with depression: a nationwide population-based retrospective cohort study in Taiwan.
    Su KP; Tang CH; Chang HC; Chiu WC; Lu N; Huang KC
    Int Clin Psychopharmacol; 2019 Jul; 34(4):170-178. PubMed ID: 30964763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contemporary management of depression.
    Andrews JM; Nemeroff CB
    Am J Med; 1994 Dec; 97(6A):24S-32S. PubMed ID: 7992823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of treatment: what do new antidepressants offer?
    Lader M
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():5-9. PubMed ID: 7622812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data.
    Berndt ER; Russell JM; Miceli R; Colucci SV; Xu Y; Grudzinski AN
    Value Health; 2000; 3(3):208-21. PubMed ID: 16464185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.